Cargando…
Adult human liver slice cultures: Modelling of liver fibrosis and evaluation of new anti-fibrotic drugs
BACKGROUND: Liver fibrosis can result in end-stage liver failure and death. AIM: To examine human liver fibrogenesis and anti-fibrotic therapies, we evaluated the three dimensional ex vivo liver slice (LS) model. METHODS: Fibrotic liver samples (F0 to F4 fibrosis stage according to the METAVIR score...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934011/ https://www.ncbi.nlm.nih.gov/pubmed/33708350 http://dx.doi.org/10.4254/wjh.v13.i2.187 |
_version_ | 1783660739700981760 |
---|---|
author | Kartasheva-Ebertz, Daria Gaston, Jesintha Lair-Mehiri, Loriane Massault, Pierre-Philippe Scatton, Olivier Vaillant, Jean-Christophe Morozov, Vladimir Alexei Pol, Stanislas Lagaye, Sylvie |
author_facet | Kartasheva-Ebertz, Daria Gaston, Jesintha Lair-Mehiri, Loriane Massault, Pierre-Philippe Scatton, Olivier Vaillant, Jean-Christophe Morozov, Vladimir Alexei Pol, Stanislas Lagaye, Sylvie |
author_sort | Kartasheva-Ebertz, Daria |
collection | PubMed |
description | BACKGROUND: Liver fibrosis can result in end-stage liver failure and death. AIM: To examine human liver fibrogenesis and anti-fibrotic therapies, we evaluated the three dimensional ex vivo liver slice (LS) model. METHODS: Fibrotic liver samples (F0 to F4 fibrosis stage according to the METAVIR score) were collected from patients after liver resection. Human liver slices (HLS) were cultivated for up to 21 days. Hepatitis C virus (HCV) infection, alcohol (ethanol stimulation) and steatosis (palmitate stimulation) were examined in fibrotic (F2 to F4) liver slices infected (or not) with HCV. F0-F1 HLS were used as controls. At day 0, either ursodeoxycholic acid (choleretic and hepatoprotective properties) and/or α-tocopherol (antioxidant properties) were added to standard of care on HLS and fibrotic liver slices, infected (or not) with HCV. Expression of the biomarkers of fibrosis and the triglyceride production were checked by quantitative reverse transcription polymerase chain reaction and/or enzyme-linked immunosorbent assay. RESULTS: The cultures were viable in vitro for 21 days allowing to study fibrosis inducers and to estimate the effect of anti-fibrotic drugs. Expression of the biomarkers of fibrosis and the progression to steatosis (estimated by triglycerides production) was increased with the addition of HCV and /or ethanol or palmitate. From day 15 of the follow-up studies, a significant decrease of both transforming growth factor β-1 and Procol1A1 expression and triglycerides production was observed when a combined anti-fibrotic treatment was applied on HCV infected F2-F4 LS cultures. CONCLUSION: These results show that the human three dimensional ex vivo model effectively reflects the in vivo processes in damaged human liver (viral, alcoholic, nonalcoholic steatohepatitis liver diseases) and provides the proof of concept that the LS examined model permits a rapid evaluation of new anti-fibrotic therapies when used alone or in combination. |
format | Online Article Text |
id | pubmed-7934011 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-79340112021-03-10 Adult human liver slice cultures: Modelling of liver fibrosis and evaluation of new anti-fibrotic drugs Kartasheva-Ebertz, Daria Gaston, Jesintha Lair-Mehiri, Loriane Massault, Pierre-Philippe Scatton, Olivier Vaillant, Jean-Christophe Morozov, Vladimir Alexei Pol, Stanislas Lagaye, Sylvie World J Hepatol Basic Study BACKGROUND: Liver fibrosis can result in end-stage liver failure and death. AIM: To examine human liver fibrogenesis and anti-fibrotic therapies, we evaluated the three dimensional ex vivo liver slice (LS) model. METHODS: Fibrotic liver samples (F0 to F4 fibrosis stage according to the METAVIR score) were collected from patients after liver resection. Human liver slices (HLS) were cultivated for up to 21 days. Hepatitis C virus (HCV) infection, alcohol (ethanol stimulation) and steatosis (palmitate stimulation) were examined in fibrotic (F2 to F4) liver slices infected (or not) with HCV. F0-F1 HLS were used as controls. At day 0, either ursodeoxycholic acid (choleretic and hepatoprotective properties) and/or α-tocopherol (antioxidant properties) were added to standard of care on HLS and fibrotic liver slices, infected (or not) with HCV. Expression of the biomarkers of fibrosis and the triglyceride production were checked by quantitative reverse transcription polymerase chain reaction and/or enzyme-linked immunosorbent assay. RESULTS: The cultures were viable in vitro for 21 days allowing to study fibrosis inducers and to estimate the effect of anti-fibrotic drugs. Expression of the biomarkers of fibrosis and the progression to steatosis (estimated by triglycerides production) was increased with the addition of HCV and /or ethanol or palmitate. From day 15 of the follow-up studies, a significant decrease of both transforming growth factor β-1 and Procol1A1 expression and triglycerides production was observed when a combined anti-fibrotic treatment was applied on HCV infected F2-F4 LS cultures. CONCLUSION: These results show that the human three dimensional ex vivo model effectively reflects the in vivo processes in damaged human liver (viral, alcoholic, nonalcoholic steatohepatitis liver diseases) and provides the proof of concept that the LS examined model permits a rapid evaluation of new anti-fibrotic therapies when used alone or in combination. Baishideng Publishing Group Inc 2021-02-27 2021-02-27 /pmc/articles/PMC7934011/ /pubmed/33708350 http://dx.doi.org/10.4254/wjh.v13.i2.187 Text en ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Basic Study Kartasheva-Ebertz, Daria Gaston, Jesintha Lair-Mehiri, Loriane Massault, Pierre-Philippe Scatton, Olivier Vaillant, Jean-Christophe Morozov, Vladimir Alexei Pol, Stanislas Lagaye, Sylvie Adult human liver slice cultures: Modelling of liver fibrosis and evaluation of new anti-fibrotic drugs |
title | Adult human liver slice cultures: Modelling of liver fibrosis and evaluation of new anti-fibrotic drugs |
title_full | Adult human liver slice cultures: Modelling of liver fibrosis and evaluation of new anti-fibrotic drugs |
title_fullStr | Adult human liver slice cultures: Modelling of liver fibrosis and evaluation of new anti-fibrotic drugs |
title_full_unstemmed | Adult human liver slice cultures: Modelling of liver fibrosis and evaluation of new anti-fibrotic drugs |
title_short | Adult human liver slice cultures: Modelling of liver fibrosis and evaluation of new anti-fibrotic drugs |
title_sort | adult human liver slice cultures: modelling of liver fibrosis and evaluation of new anti-fibrotic drugs |
topic | Basic Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934011/ https://www.ncbi.nlm.nih.gov/pubmed/33708350 http://dx.doi.org/10.4254/wjh.v13.i2.187 |
work_keys_str_mv | AT kartashevaebertzdaria adulthumanliversliceculturesmodellingofliverfibrosisandevaluationofnewantifibroticdrugs AT gastonjesintha adulthumanliversliceculturesmodellingofliverfibrosisandevaluationofnewantifibroticdrugs AT lairmehiriloriane adulthumanliversliceculturesmodellingofliverfibrosisandevaluationofnewantifibroticdrugs AT massaultpierrephilippe adulthumanliversliceculturesmodellingofliverfibrosisandevaluationofnewantifibroticdrugs AT scattonolivier adulthumanliversliceculturesmodellingofliverfibrosisandevaluationofnewantifibroticdrugs AT vaillantjeanchristophe adulthumanliversliceculturesmodellingofliverfibrosisandevaluationofnewantifibroticdrugs AT morozovvladimiralexei adulthumanliversliceculturesmodellingofliverfibrosisandevaluationofnewantifibroticdrugs AT polstanislas adulthumanliversliceculturesmodellingofliverfibrosisandevaluationofnewantifibroticdrugs AT lagayesylvie adulthumanliversliceculturesmodellingofliverfibrosisandevaluationofnewantifibroticdrugs |